GeneDx Holdings Corp. 8-K

What Happened GeneDx Holdings Corp. filed an 8-K on March 2, 2026 disclosing that on February 27, 2026 it entered into a Loan Agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C., Wilmington Trust as agent, and the participating lenders. The Loan Agreement funds a $100.0 million term loan used to repay the company’s existing term loan under its October 27, 2023 credit agreement and is expected to be used for other balance sheet optimization efforts and general corporate purposes.

Key Details

• Term loan amount: $100.0 million, funded on February 27, 2026.
• Interest: Term SOFR + 4.50% with a SOFR floor of 1.50%; default interest adds 2.00% if an event of default is continuing.
• Maturity and security: 5-year maturity from closing; obligations guaranteed by subsidiaries and secured by a first lien on substantially all assets.
• Covenants and prepayments: Includes customary reps/covenants, mandatory prepayment triggers (e.g., change of control, certain indebtedness or asset sales), optional prepayment by the company subject to yield protection premiums, and a minimum liquidity covenant of $50.0 million.

Why It Matters This transaction replaces GeneDx’s prior term loan and creates a new $100M secured financial obligation that will affect the company’s interest costs, liquidity profile and covenant package. Investors should note the fixed margin over SOFR, the five-year maturity, the $50M minimum liquidity requirement and the first-lien security—each of which can influence financial flexibility and risk if business or market conditions change. The loan proceeds are intended to optimize the balance sheet and support general corporate needs, but the agreement also includes typical lender protections (prepayment rules and default remedies) that could accelerate repayment obligations under certain circumstances.